To show the most common causes of bacteriemia in hospitalized patients, as well as their sensitivity to antimicrobial agents. The research data were extracted from official reports produced by Microbiological Laboratory in Clinical Centre Kragujevac. Isolation and identification of the causes were performed with standard microbiological methodology. Sensitivity to antimicrobial medication was tested using disc diffusion. Interpretation and inhibition zones of antibiogram were done in accordance with guidelines of US Clinical and Laboratory Standards Institute (CLSI). A descriptive epidemiological approach was used in the research. The collected data were processed using the appropriate software application. Amongst the processed samples, a significant presence of Staphylococcus spp. was found (coagulase-negative 35,8% and coagulase positive 11,7%). Over 60% of Staphylococcus aureus isolates were resistant to meticillin. Enterococcus spp, isolated in 11,7% of all isolates, in more than 50% of cases was sensitive to ampicillin, with approximate isolate vancomycin sensitivity of 90%. The isolated Klebsiellà spp strains produced high degrees of Extended-Spectrum â-Lactamases (ESBL) and showed resistance to third-generation cephalosporins, aminoglycosides and ciprofloxacin, with 100% sensitivity to carbapenem. Pseudomonas spp and Acinetobacter spp were less represented (5.8% and 5.4%) but these neither pathogens were exempt to antimicrobial resistance.The research indicated that causes of hospital infections should be continuously monitored.
Salgado CD. The risk of developing a vancomycin-resistant Enterococcus bloodstream infection for colonized patients. Am J Infect Control. 36(10).
2.
Wareham DW, Bean DC, Khanna P, Hennessy EM, Krahe D, Ely A, et al. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance.
3.
Jang TN, Lee SH, Huang CH, Lee CL, Chen WY. Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit: a case-control study. J Hosp Infect. 73(2):143–50.
4.
Kim YA, Choi JY, Kim CK, Kim CO, Kim MS, Choi SH, et al. Risk factors and outcomes of bloodstream infections with metallo-beta-lactamase-producing Acinetobacter. Scand J Infect Dis. 40(3):234–40.
5.
6.
Delden C. Pseudomonas aeruginosa bloodstream infections: how should we treat them? Int J Antimicrob Agents. 30(1).
7.
8.
Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control. 34(5 Suppl 1).
9.
Yang K, Guglielmo BJ. Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms. Ann Pharmacother. 41(9):1427–35.
10.
Bellíssimo-Rodrigues F, Gomes AC, Passos AD, Achcar JA, Perdoná Gda S, Martinez R. Clinical outcome and risk factors related to extended-spectrum beta-lactamase-producing Klebsiella spp. infection among hospitalized patients. Mem Inst Oswaldo Cruz. 101(4):415–21.
11.
Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother. 49(2):760–6.
12.
Olivier CN, Blake RK, Steed LL, Salgado CD. Risk of vancomycin-resistant Enterococcus (VRE) bloodstream infection among patients colonized with VRE. Infect Control Hosp Epidemiol. 29(5):404–9.
13.
Damani NN. Manual of Infection Control Procedures. :126–9.
14.
Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Comment in: Clin Infect Dis. 46(5):668–74.
15.
16.
Han SH, Chin BS, Lee HS, Jeong SJ, Choi HK, Kim CO, et al. Vancomycin-resistant enterococci bacteremia: risk factors for mortality and influence of antimicrobial therapy on clinical outcome. J Infect. 58(3):182–90.
17.
Mee-Marquet N, C E, J L, L A, AS D, B L, et al. Staphylococcus aureus strains isolated from bloodstream infections changed significantly in 2006. J Clin Microbiol. 45(3):851–7.
18.
19.
Henderson DK. Managing methicillin-resistant staphylococci: a paradigm for preventing nosocomial transmission of resistant organisms. Am J Med. 19(6 Suppl 1).
20.
Huang YC, Chou YH, Su LH, Lien RI, Lin TY. Methicillin-resistant Staphylococcus aureus colonization and its association with infection among infants hospitalized in neonatal intensive care units. Pediatrics. 118(2):469–74.
21.
Wyllie DH, Crook DW, Peto TE. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study. BMJ. 333(7562).
22.
Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection? Infect Control Hosp Epidemiol. 30(5):453–60.
23.
Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary. J Infect Dis. 2008;198(3):336-43.
24.
25.
Nickerson EK, Wuthiekanun V, Wongsuvan G, Limmathurosakul D, Srisamang P, Mahavanakul W, et al. Factors predicting and reducing mortality in patients with invasive Staphylococcus aureus disease in a developing country. PLoS One. 4(8).
26.
Prica M, Varagiæ-Stojanoviæ Z, Maziæ N. Pregled izolata iz hemokultura u periodu jul 2000.-jun 2002. Acta Clinica. 1(3):29–34.
27.
28.
Dellit TH, Owens RC, JE M, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for developing an Institutional Program to Enhance Antimicrobial Stewardship. Clin Infect Dis. 44(2):159–77.
29.
Maki DG, Safdar N, Ebert SC. Antimicrobial Resistance: Walking Up to the Challenge Supplement: Prevalence, Consequences and Solutions. Pharmacotherapy. 27(121).
30.
Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 50(4):1257–62.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
